Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617240 · ClinicalTrials.gov registry record · Phase 2
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
A Phase 2 study of Weight Gain, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00617240: Completed Phase 2 study of Weight Gain, sponsored by University of North Carolina, Chapel Hill.
NCT00617240 is a Phase 2 study of Weight Gain that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 9 participants, below the 221-participant average among 38 other Weight Gain trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00617240, a Phase 2 study of Weight Gain, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to determine whether starting metformin in conjunction with a second-generation antipsychotic (SGA) and providing information about healthy eating and activity will prevent or reduce the amount of weight gain and the metabolic changes in adolescent youth typically seen with second-generation antipsychotic medication.
Primary Outcome
Change in BMI-Body Mass Index (BMI) is a measure of body fat based on height, weight,gender and chronological age. Change in BMI is calculated as 24 weeks BMI minus the baseline BMI.
Conditions Studied
Interventions
- DRUG placebo
- DRUG metformin
Study Locations (1)
North Carolina
- University of North Carolina, Department of Psychiatry - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
What the finished NCT00617240 record still lists
NCT00617240 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 221-participant average among 38 other Weight Gain trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Weight Gain appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00617240 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00617240 about?
NCT00617240 is a clinical study titled "Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth". The purpose of this pilot study is to determine whether starting metformin in conjunction with a second-generation antipsychotic (SGA) and providing information about healthy eating and activity will prevent or reduce the amount of weight gain and the metabolic changes in adolescent youth typically ...
What is the current status of trial NCT00617240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2007-01. Estimated completion is 2012-10.
What conditions does trial NCT00617240 study?
This clinical trial studies the following conditions: Weight Gain.
What interventions are being tested in trial NCT00617240?
The interventions under investigation include: placebo (DRUG), metformin (DRUG).
Who is sponsoring clinical trial NCT00617240?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00617240 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Gain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00617240's enrollment target sits among peer trials
9 38th of 38 higher than 1 of 38 other Weight Gain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Weight Gain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Incretin Microdosing for Cardiometabolic Health in People With HIV
RECRUITING · Phase 2
-
A Novel Obesity Prevention Program for High-Risk Infants in Primary Care
RECRUITING · Phase 2
-
Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers
RECRUITING · Phase 2
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
RECRUITING · NA
-
Testing Responses of Young Adults to Intervention Messages for Promoting Physical Activity Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia